Enliven Therapeutics (ELVN) CMO exercises options, sells stock
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share and on the same date sold 5,000 shares in two open-market transactions at weighted average prices of $58.3717 and $59.3465. Following the option exercise, she held 111,268 option shares directly. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 5,000 shares ($281K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Collins Helen Louise
Role
CHIEF MEDICAL OFFICER
Sold
5,000 shs ($293K)
Approx. gross sale proceeds
$293K
Approx. exercise cost
$12K
Approx. pre-tax spread
$281K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F6 | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 5,000 | $2.48 | $12K |
| Sale | Common Stock F1, F3, F2 | 3,900 | $58.3717 | $228K |
| Sale | Common Stock F1, F4, F5 | 1,100 | $59.3465 | $65K |
Holdings After Transaction:
Stock Option (right to buy) — 111,268 shares (Direct);
Common Stock — 25,000 shares (Direct)
Footnotes (6)
- F1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F3. This transaction was executed in multiple trades at prices ranging from $57.895 to $58.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4. This transaction was executed in multiple trades at prices ranging from $58.985 to $59.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F5. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Key Figures
Options Exercised: 5,000 shares
Exercise Price: $2.48 per share
Shares Sold (Tranche 1): 3,900 shares
+5 more
8 metrics
Options Exercised
5,000 shares
Stock option exercise into common stock on August 17, 2026
Exercise Price
$2.48 per share
Exercise price of the 5,000-share stock option
Shares Sold (Tranche 1)
3,900 shares
Common stock sold at weighted average price of $58.3717
Weighted Average Price (Tranche 1)
$58.3717 per share
First sale tranche, prices ranged from $57.895 to $58.84
Shares Sold (Tranche 2)
1,100 shares
Common stock sold at weighted average price of $59.3465
Weighted Average Price (Tranche 2)
$59.3465 per share
Second sale tranche, prices ranged from $58.985 to $59.535
Options Remaining
111,268 shares
Total option shares held directly after the exercise
Option Expiration
June 17, 2031
Expiration date of the exercised stock option grant
Key Terms
Rule 10b5-1 trading plan, restricted stock units (RSUs), weighted average sale price, contingent right to receive one share
4 terms
Rule 10b5-1 trading plan regulatory
"were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units (RSUs) financial
"Certain of these securities are restricted stock units (RSUs). Each RSU"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
FAQ
What did ELVN’s Chief Medical Officer report on this Form 4?
Helen Louise Collins reported exercising options for 5,000 ELVN shares at $2.48 per share and selling 5,000 shares of Enliven Therapeutics common stock in open-market transactions on August 17, 2026.
What stock options did the Enliven Therapeutics (ELVN) insider exercise?
She exercised a stock option for 5,000 ELVN shares of common stock at an exercise price of $2.48 per share. After this derivative transaction, she directly held 111,268 option shares subject to the same option grant, which expires on June 17, 2031.
Were the ELVN insider transactions made under a Rule 10b5-1 trading plan?
Yes. The option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted by Helen Louise Collins on October 19, 2025, indicating they followed a pre-arranged trading schedule.
How many Enliven Therapeutics (ELVN) options remain after the transaction?
After the reported option exercise, Helen Louise Collins held 111,268 option shares directly under the referenced stock option, which is fully vested and exercisable and carries an expiration date of June 17, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
